



# COVID-19 Vaccine: Booster Training

**Vermont Department of Health –  
October 28, 2021**

*Merideth Plumpton, RN - Nurse Program Coordinator*

*Meghan Knowles, MS - Communication and Training Coordinator*

# Agenda

- ACIP Recommendations
  - Boosters
  - Mix and Match
  - Additional Doses (3<sup>rd</sup> doses) and Intervals
- Vermont Implementation
- Moderna
  - Administration Timing and Training
  - VIMS documentation of full and half doses
  - Ancillary supplies
- Pfizer Administration Timing and Training
- Janssen Administration Timing
- Inventory Management and Reporting
- Resources
- Q+A

# Booster Doses – ACIP Recommendations

# ACIP Recommendation Timeline

## Booster doses

- 9/22/21 FDA authorized booster doses for Pfizer
- 10/20/21 FDA authorized booster doses for Moderna and Janssen
- ACIP gave recommendations for Moderna, Janssen, and mix and match boosters on 10/21/21 [ACIP October 20-21, 2021 Presentation Slides | Immunization Practices | CDC](#)

***Additional Dose (3<sup>rd</sup> dose):** The immune response to the primary series was weak and provided limited protection.*

***Booster Dose:** evidence indicates that protection from the primary series has declined over time.*

# ACIP Recommendations - Boosters

## Pfizer and Moderna

A single COVID-19 vaccine booster dose is recommended 6 months or more after completion of the mRNA primary series, based on risk groups.

- individuals age 65 years and older should receive a booster;
- individuals age 18–64 years at high risk of severe COVID-19 should receive a booster; and
- individuals age 18–64 years who live or work in high-risk settings may receive a booster.

## Janssen (Johnson & Johnson)

A single COVID-19 vaccine booster dose is recommended for persons 18 years of age and older, at least 2 months after receipt of the initial Janssen dose.

See [CDC's Who Is Eligible for a COVID-19 Vaccine Booster Shot?](#) for more information

# Moderna half dose for boosters

Moderna was approved for a half dose for boosters

- Primary series is 0.5ml (100mcg)
- Additional dose for immunocompromised is 0.5ml (100mcg)
- Booster dose 6 months following completion of a primary series (Pfizer, Moderna or Janssen), or an additional dose (Pfizer or Moderna), is 0.25ml (50mcg)

# Interchangeability of COVID-19 Vaccine Boosters

- Any currently FDA-approved or FDA-authorized COVID-19 vaccine can be used for boosters when indicated; ACIP and CDC do not state a product preference.
- People may consider the benefits and risks of each product and discuss with their healthcare provider which product is most appropriate for them.
- “Mix and Match” is approved for boosters only. Additional doses (3<sup>rd</sup> doses) for immunocompromised individuals should be completed with the same product.

# Mix and Match Booster Doses

## Pfizer or Moderna as primary series

Pfizer, or Moderna COVID-19 Vaccine recipients who qualify may receive a single booster dose of Janssen COVID-19 Vaccine, Moderna COVID-19 Vaccine (**half dose**) or Pfizer-BioNTech COVID-19 Vaccine at least six months after receiving their initial COVID-19 Vaccine primary 2 dose vaccination.

## Janssen as primary series

Janssen COVID-19 Vaccine recipients who qualify may receive a single booster dose of Janssen COVID-19 Vaccine, Moderna COVID-19 Vaccine (**half dose**) or Pfizer-BioNTech COVID-19 Vaccine at least two months after receiving their Janssen COVID-19 Vaccine primary vaccination.



# Immunocompromised – Additional (3<sup>rd</sup>) doses (mRNA only)

## Pfizer-BioNTech or Moderna

- All doses of the primary series and the additional dose (3<sup>rd</sup> dose) **should** be completed with the same product.
- If receiving Moderna as additional dose it is a full 0.5ml or 100mcg dose.
- Moderately and severely immunocompromised people aged  $\geq 18$  years who completed an mRNA COVID-19 vaccine primary series and received an additional (3<sup>rd</sup>) mRNA vaccine dose **may** receive a single COVID-19 **booster** dose (Pfizer-BioNTech, Moderna or Janssen) at least 6 months after completing their third mRNA vaccine dose.
- In such situations, people who are moderately and severely immunocompromised may receive a total of **four** COVID-19 vaccine doses.

## Janssen

- Moderately and severely immunocompromised people aged  $\geq 18$  years who received a single dose Janssen COVID-19 vaccine primary series **should** receive a single COVID-19 **booster** vaccine, (Pfizer-BioNTech, Moderna or Janssen) at least 2 months (8 weeks) after receiving their initial Janssen primary dose. This is not considered an additional dose and the series may be mixed.
- **People who received Janssen will only receive two doses of a COVID-19 vaccine, regardless of immunocompromised status.**

# Intervals and when to repeat doses

## Primary series

- If the second dose of a vaccine is given earlier than the 4-day grace period (i.e., <17 days for Pfizer-BioNTech or <24 days for Moderna), the second dose **should** be repeated. The repeat dose at recommended minimum interval from erroneous dose.
- If the first dose was an mRNA COVID-19 vaccine but is unable to complete the series with either the same or different mRNA COVID-19 vaccine (e.g., due to contraindication), a single dose of Janssen COVID-19 vaccine may be considered at a minimum interval of 28 days from the mRNA COVID-19 vaccine dose.

## Additional dose

- The additional dose (i.e., third dose) of an mRNA COVID-19 vaccine should be administered at least 28 days after completion of the initial 2-dose mRNA COVID-19 primary. If the additional dose of an mRNA COVID-19 vaccine is given fewer than 24 days after the second dose (i.e., administered earlier than the 4-day grace period), the additional dose **should** be repeated.

## Booster dose

- If a heterologous vaccine product is used for the booster dose, the interval should follow the interval recommended by the primary series (e.g., a single dose Janssen primary series can receive an mRNA COVID-19 vaccine booster dose at least 2 months (8 weeks) after completing their Janssen primary series).
- If the booster dose is given earlier than the recommended interval (i.e., <6 months after a second mRNA primary vaccine dose and <2 months after a Janssen primary vaccine dose), the booster dose does **not** need to be repeated.

[Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC – Appendix A](#) has a chart explaining when it is appropriate to repeat a dose.

# Coadministration with other vaccines

- **COVID-19 vaccines may be administered without regard to timing of other vaccines.** This includes simultaneous administration of COVID-19 vaccine and other vaccines on the same day.
  - Including flu vaccine, shingles vaccine, and pneumococcal vaccines, among others
- **If multiple vaccines are administered at a single visit, administer each injection in a different injection site.**
- [See CDC Best practices](#) for more information on coadministration of vaccines.

# Booster Doses – Vermont Implementation

# Vermont Plan

Vermont will offer booster doses widely at community clinics, pharmacies, and primary care offices.

Booster dose scheduling is open now at Health Department website and through pharmacy websites.

Mix and match registration will be open November 1<sup>st</sup>



# Advising your patients

The best place to get a booster/additional dose (3<sup>rd</sup> dose) may depend on where a patient received the primary series.

- If primary series was through Vermont registration system (community clinics) patients may:
  - register for a booster of the same series through the state system immediately.
  - register for a “mix and match” booster as of November 1<sup>st</sup>.
  - Receive vaccine at a pharmacy or administering PCP location.
- If primary series was NOT through the Vermont registration system, patient may:
  - Receive vaccine at a pharmacy or administering PCP location.
  - Call the Health Department to register for a community clinic
    - 855-722-7878, Mon - Fri 8:15 am - 4:30 pm, Sat and Sun 10:00 am - 3:00 pm

# Vermont will continue to follow ACIP recommendations, with important extensions

- Janssen as primary series - anyone over 18 years old should receive a booster.
- Moderna or Pfizer as primary series - anyone is eligible who is
  - 65+ OR
  - 18+ AND
    - reside or work in a long-term care facility OR
    - at [high risk of severe COVID](#) OR
    - work in [high-risk occupations](#) OR
    - are BIPOC OR live with a BIPOC
- Booster shots are especially encouraged for people with [certain medical conditions](#)<sup>1</sup>, who work in a [high-risk setting](#)<sup>2</sup> or who are Black, Indigenous or a person of color (BIPOC) or are age 18 or older and live with someone who is BIPOC.
  - <sup>1</sup> - <https://www.healthvermont.gov/covid-19/faqs#booster-medical>
  - <sup>2</sup> - <https://www.healthvermont.gov/covid-19/faqs#booster-jobs>
- Criteria for eligibility is self-attestation. No patient will need a provider office to provide proof or a code.

# Booster Doses – Moderna



# Moderna Administration and Timing

Moderna		
Dosing	Eligibility	Timing
Primary series (100 µg/0.5 mL)	Anyone age 18+	2 doses separated by 28 days
Additional dose (3 <sup>rd</sup> dose) (100 µg/0.5 mL)	<i>Must be both</i> <ul style="list-style-type: none"> <li>• Ages 18+ <i>AND</i></li> <li>• Moderately to severely immunocompromised</li> </ul>	28+ days after second dose
Booster – HALF dose (50 µg/0.25 mL)	<i>Either</i> <ul style="list-style-type: none"> <li>• 65+ <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> reside or work in a long term care facility <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> at high risk of severe COVID <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> work in high-risk occupations <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> are BIPOC <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> live with a BIPOC</li> </ul>	6+ months after primary series
Mix and Match booster option	Those meeting eligibility criteria for booster may opt for <ul style="list-style-type: none"> <li>• “Full dose” of Pfizer-BioNTech (0.3 mL) <i>OR</i></li> <li>• “Full dose” of Johnson &amp; Johnson (0.5 mL)</li> </ul>	6+ months after second dose

# Moderna Booster Dose Waste Reporting

The [Moderna Waste Reporting in VIMS tool](#) has been created to assist practices in planning and reporting waste accurately. You may need to adjust your current tracking systems to comply with the reporting requirements.

- Administer booster doses from the existing Moderna supply of 14-dose or 10-dose vials.
- Vials cannot be punctured more than 20 times.
- Report waste based on doses administered (half and full doses), NOT discarded volume.
- You will report waste only when fewer than 14/10 doses (half or full doses) are administered out of a vial.
- When 14/10 doses (half or full doses) or more are administered out of a vial, you will not report waste. This is true even if full doses are discarded.
- You will never document more than 14/10 doses as administered in VIMS, even if more doses are given. You will not “adjust in” any doses.
- When the beyond use time (12 hrs after puncture) passes, use the [Moderna Waste Reporting in VIMS](#) tool to determine the number of doses to report as waste.
- On Wednesday, during weekly COVID-19 vaccine reconciliation, report the wasted doses determined as **Adjust Out > Waste > No Eligible Person in VIMS**.

<https://www.healthvermont.gov/sites/default/files/documents/pdf/HS-IZ-Moderna-booster-reporting-guidance.pdf>

# Moderna Ancillary Kits

Ancillary kits will be doubled to allow for booster (half dose) or full dose administration.

- Current ancillary kits should have sufficient 1 mL syringes to assure accurate extraction of 0.25mL booster doses. If this is not the case, please reach out to [AHS.VDHCovidVaxDistribution@vermont.gov](mailto:AHS.VDHCovidVaxDistribution@vermont.gov).
- Future orders of Moderna will include sufficient ancillary supplies to extract 20 doses of vaccine per vial, which is the maximum number of times a single vial can be punctured.
- **When possible, please use 3 mL syringes for extraction of primary series doses to ensure you have an adequate supply of 1 mL syringes to support extraction of booster doses from a Moderna vial.**

# Moderna Trainings

Join Moderna for a webinar for vaccination providers to learn more about the Moderna COVID-19 Vaccine booster dose, which has been authorized for emergency use in the United States. There will be no continuing education offered for this webinar. Please register at the link below for one of our available sessions.

**Webinar:** Important updates on the mRNA-1273 50 µg Booster Dose

Thursday, October 28<sup>th</sup> at 12pm ET

[https://ashfieldmeetings.zoom.us/webinar/register/WN\\_jZORMyxPTByhn71x5L3wAw](https://ashfieldmeetings.zoom.us/webinar/register/WN_jZORMyxPTByhn71x5L3wAw)

Thursday, November 4<sup>th</sup> at 3pm ET

[https://ashfieldmeetings.zoom.us/webinar/register/WN\\_YwgXNQ-dQ7SheJhzngW3uw](https://ashfieldmeetings.zoom.us/webinar/register/WN_YwgXNQ-dQ7SheJhzngW3uw)

Thursday, November 11<sup>th</sup> at 12pm ET

[https://ashfieldmeetings.zoom.us/webinar/register/WN\\_6uhSZx1oSfKqharrkvLU0Q](https://ashfieldmeetings.zoom.us/webinar/register/WN_6uhSZx1oSfKqharrkvLU0Q)

# Booster Doses – Pfizer BioNTech

# Pfizer Administration and Timing

## Pfizer- BioNTech

Dosing	Eligibility	Timing
Primary series (30 µg/0.3 mL)	Anyone age 12+	2 doses separated by 21 days
Additional dose (3 <sup>rd</sup> dose) (30 µg/0.3 mL)	<i>Must be both</i> <ul style="list-style-type: none"> <li>• Ages 12+ <i>AND</i></li> <li>• Moderately to severely immunocompromised</li> </ul>	28+ days after second dose
Booster (30 µg/0.3 mL)	<i>Either</i> <ul style="list-style-type: none"> <li>• 65+ <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> reside or work in a long-term care facility <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> at high risk of severe COVID <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> work in high-risk occupations <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> are BIPOC <i>OR</i></li> <li>• <i>Both</i> 18+ <i>AND</i> live with a BIPOC</li> </ul>	6+ months after primary series
Mix and Match booster option	Those meeting eligibility criteria for booster may opt for <ul style="list-style-type: none"> <li>• “Half dose” of Moderna (0.25 mL) <i>OR</i></li> <li>• “Full dose” of Johnson &amp; Johnson (0.5 mL)</li> </ul>	6+ months after second dose

# Pfizer Trainings

Pfizer Vaccines US Medical Affairs will be hosting Immunization Site Training Sessions for All Providers on the Storage, Handling, & Administration for **Current & Potential New Formulations of our COVID-19 vaccine** (with our partner BioNTech).

These sessions will be updated to reflect new information and changes that evolve. Such updates will be identified at the start of each session and further explained during each presentation.

The Immunization Program will include all updated Pfizer training links in communications

<a href="#"><u>Attendee link – October 29 – 12 PM ET</u></a>	cnRBrmGr324
<a href="#"><u>Attendee link – November 1 – 5 PM ET</u></a>	g9ZmgHaip32
<a href="#"><u>Attendee link – November 2 – 5 PM ET</u></a>	sJDZQERp325
<a href="#"><u>Attendee link – November 3 – 12 PM ET</u></a>	82qdN3PppPp
<a href="#"><u>Attendee link – November 4 – 12 PM ET</u></a>	Y4ZkXdh2bz7
<a href="#"><u>Attendee link – November 5 – 12 PM ET</u></a>	rJSpNPts332

# Booster Doses – Janssen



# Janssen Administration and Timing

Janssen		
Dosing	Eligibility	Timing
Primary series (5×/10 <sup>10</sup> vp/0.5 mL)	Anyone age 18+	1 dose
Additional dose	Not Applicable	Not Applicable
Booster (5×/10 <sup>10</sup> vp/0.5 mL)	Anyone age 18+	2+ months after initial dose
Mix and Match booster option	Those meeting eligibility criteria for booster may opt for <ul style="list-style-type: none"> <li>• “Full dose” of Pfizer-BioNTech (0.3 mL) <i>OR</i></li> <li>• “Full dose” of Johnson &amp; Johnson (0.5 mL)</li> </ul>	2+ months after initial dose

A person who received one primary dose of Janssen COVID-19 vaccine should not receive more than two COVID-19 vaccine doses.

# **Booster Doses – Reporting, Ordering, and Inventory Management**

# Beyond Use Date/Time

## Expiration Date

- Associated with a specific lot number and might be extended as new data is obtained.
- Change is reflected in VIMS and communicated by the Immunization Program.

## Beyond Use Date

- When Pfizer and Moderna vaccines are moved out of permanent storage and into refrigerated temperatures, they have a Beyond Use Date that should be documented clearly.
- Janssen permanent storage is in the refrigerator, and so Beyond Use Dates do not apply.
- ***Tracking and adherence to a Beyond Use Date is the practice's responsibility and will not be reflected in VIMS.***

## Beyond Use Time

- All COVID-19 vaccines have Beyond Use Times associated with dilution/vial puncture, after which the vaccine must be disposed of.

# Vermont Immunization Registry

- If you manually enter historical records, you **must** enter it accurately.
  - Please **DO NOT**:
    - Record an approximate date based on patient testimony or estimate shot dates
    - Use the date of the patient office visit
  - Please **DO**:
    - Record all doses your location administers quickly and accurately.
    - Record a historical dose if you have an accurate record of what occurred (vaccine card, registry information, or other documentation). Note: Vaccine Lot #'s are case sensitive.

# Vermont Immunization Registry: Vaccine Names and CPT/CVX Codes

A list that matches the vaccine names or codes in the Vermont Immunization Registry with the brand name/common names. Intended as a tool to guide accurate vaccine reporting for practices and organizations sending data from electronic medical records. For questions, contact Immunization Registry Manager at (802) 951-4094.

Vaccine Trade Name or Common Trade Name	Best IMR Selection	Manufacturer	CVX Code	CPT Code
<b>COVID-19 Vaccines</b>				
Moderna COVID-19 Vaccine®	COVID-19, mRNA LNP-S, PF, Moderna	Moderna	207	91301
Pfizer COVID-19 Vaccine®	COVID-19, mRNA LNP-S, PF, Pfizer	Pfizer	208	91300
Janssen COVID-19 Vaccine®	COVID-19 vaccine, vector-nr, Janssen	Janssen	212	91303
<b>Pfizer COVID-19 Vaccine for 5-11 yrs®</b>	<b>COVID-19, mRNA, Pfizer (5-11 years)</b>	<b>Pfizer</b>	<b>218</b>	<b>91307</b>

- Please make sure you are reporting the correct CVX code for the vaccine administered.
- As new EUA's are issued, up to date CVX codes can be found on the IMR website under user support:
  - [www.healthvermont.gov/health-statistics-vital-records/registries/immunization#user-support](http://www.healthvermont.gov/health-statistics-vital-records/registries/immunization#user-support)

# Booster Doses – Resources

# Clinical considerations - resources

- [Interim Clinical Considerations for Use of COVID-19 Vaccines](#)
- [Management of Anaphylaxis at COVID-19 Vaccination Sites:](#)
  - Preparing for allergic reactions
  - Benadryl and EPI pens (Adult and Jr if vaccinating pediatrics)
- [COVID-19 clinical consultation](#)
- [Immunization Action Coalition: Ask the Experts](#)

# Resources

COCA Call Webinar October 26, 2021 - What Clinicians Need to Know about the Recent Updates to CDC's Recommendations for COVID-19 Boosters

- [Recording](#)
- [Slides](#)

[Who Is Eligible for a COVID-19 Vaccine Booster Shot? | CDC](#)

<https://www.modernatx.com/covid19vaccine-eua/providers/dear-hcp-letter.pdf>

[COVID-19 Vaccine: Quick Reference Guide for Healthcare Professionals \(cdc.gov\)](#)

CDC standing order templates have been updated

- [Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine \(cdc.gov\)](#)
- [Moderna COVID-19 Vaccine: Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older \(cdc.gov\)](#)
- [Janssen COVID-19 Vaccine \(Johnson & Johnson\): Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older \(cdc.gov\)](#)



# Questions?

## Vaccine Storage and Handling, Vaccine Specific Information

E-mail: [AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov)

Phone: 1-800-640-4374

## Vaccine Distribution

will send COVID-19 confirmation, send inquiries to main inbox

E-mail: [AHS.VDHCovidVaxDistribution@vermont.gov](mailto:AHS.VDHCovidVaxDistribution@vermont.gov)

## Immunization Registry and Reporting

E-mail: [IMR@vermont.gov](mailto:IMR@vermont.gov)

Phone: 1-888-688-4667

# Pfizer BioNTech Storage and Handling – current formulation

## Before Dilution

- Permanent storage is ultracold (-80°C to -60°C)
- Vials may be stored at limited freezer temperatures (-25°C to -15°C) for a cumulative time of up to 2 weeks.
- Moving between freezer and ultra cold may happen only once.
- Vials may be stored in the refrigerator (2°C to 8°C) for up to **1 month**.
- Undiluted vials may be stored at room temperature for no more than 2 hours.

## After Dilution

- If frozen, vials may be thawed in the refrigerator (2-3 hrs), or at room temperature (30 min).
- After dilution, store vials between 2°C to 25°C and use within 6 hours of dilution.
- Any remaining doses from a punctured vial must be disposed of after 6 hours.

# Janssen Storage and Handling

## Before puncture

- Permanent storage is in the refrigerator (2°C to 8°C)
- Vaccine may still be frozen upon delivery but should be placed in the refrigerator.
- Unpunctured vials may be stored at room temperature (up to 25°C) for 12 hours.

## After puncture

- After puncture, store vials between 2°C to 8°C and use within 6 hours **OR** stored at room temperature (up to 25°C) for 2 hours.
- Room temperature and refrigerated temperatures may not be combined.
- Once at room temperature the vaccine must be used within 2 hours.

# Moderna Storage and Handling

## Before puncture

- Permanent storage is in the freezer (-50°C to -15°C)
- Vials may be stored in the refrigerator (2°C to 8°C) for 30 days.
- Unpunctured vials may be stored at room temperature (up to 25°C) for 24 hours.
- Once thawed vaccine may not be refrozen.

## After puncture

- If frozen, vials may be thawed in the refrigerator (2.5 hrs), or at room temperature (1 hr).
- After puncture, store vials between 2°C to 25°C and use within 12 hours.
- Any remaining doses from a punctured vial must be disposed of after 12 hours.

# CDC COVID-19 Training Modules for CE credit



## COVID-19 Vaccine Training Modules



[COVID-19 Vaccine Training: General Overview of Immunization Best Practices for Healthcare Providers](#) (Updated October 27, 2021)



[Janssen COVID-19 Vaccine \(Johnson & Johnson\): What Healthcare Professionals Need to Know](#) (Updated October 27, 2021)



[Moderna COVID-19 Vaccine: What Healthcare Professionals Need to Know](#) (Updated October 27, 2021)



[Pfizer-BioNTech COVID-19 Vaccine: What Healthcare Professionals Need to Know](#) (Updated October 27, 2021)

<https://www2.cdc.gov/vaccines/ed/covid19/>

## Health Department Resources

Temperature Excursion Protocol | VDH:

<https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-Vaccine-Temp-Excursion-Protocol.pdf>

Vaccine Storage and Handling for Off-site Clinics | VDH:

<https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-Vaccine-Off-Site-Clinic-Guidance.pdf>

Hourly Paper Temperature Log | VDH:

[https://www.healthvermont.gov/sites/default/files/documents/pdf/ID\\_IZ\\_INF\\_OHCP\\_VCPVAVP\\_Hourly%20Vaccine%20Temperature%20Log.pdf](https://www.healthvermont.gov/sites/default/files/documents/pdf/ID_IZ_INF_OHCP_VCPVAVP_Hourly%20Vaccine%20Temperature%20Log.pdf)

Tracking Vaccine Inventory | VDH :

<https://www.healthvermont.gov/covid-19/health-care-professionals/vaccine-information-health-care-professionals>

Minimizing Waste Policy | VDH :

<https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-Vaccine-Minimize-Waste-Policy.pdf>

## Health Department Resources

Patients who have NOT received any COVID-19 doses | VDH IMR:

[https://www.healthvermont.gov/sites/default/files/documents/pdf/IMR\\_Patient\\_List\\_By\\_DOB\\_%20Report\\_Guide-COVID-19.pdf](https://www.healthvermont.gov/sites/default/files/documents/pdf/IMR_Patient_List_By_DOB_%20Report_Guide-COVID-19.pdf)

Patients who have missed/are late for a second COVID-19 dose | VDH IMR:

[https://www.healthvermont.gov/sites/default/files/documents/pdf/IMR\\_How%20to%20Use%20the%20Not%20Up%20To%20Date%20Report%20-COVID.pdf](https://www.healthvermont.gov/sites/default/files/documents/pdf/IMR_How%20to%20Use%20the%20Not%20Up%20To%20Date%20Report%20-COVID.pdf)

Patients who HAVE received a COVID-19 dose | VDH IMR:

[https://www.healthvermont.gov/sites/default/files/documents/pdf/IMR\\_Patients\\_Immunized\\_By\\_Series\\_%20Report\\_Guide-COVID-19.pdf](https://www.healthvermont.gov/sites/default/files/documents/pdf/IMR_Patients_Immunized_By_Series_%20Report_Guide-COVID-19.pdf)

Vaccine Information for Health Care Professionals | VDH:

<https://www.healthvermont.gov/covid-19/health-care-professionals/vaccine-information-health-care-professionals>

## Additional Health Department Resources

### State-Supplied Temperature Monitoring Resources

<https://www.healthvermont.gov/immunizations-infectious-disease/immunization-health-care-professionals/vaccine-storage-and-handling>

### COVID-19 VIMS User Guide

<https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-VIMS-Hospital-User-Guide.pdf>

### COVID-19 Only Reconciliation Guide

<https://www.healthvermont.gov/sites/default/files/documents/pdf/COVID19-VIMS-Reconcile-Quick-Guide.pdf>



## External Resources

Pre-vaccination Screening Form | CDC:

<https://www.cdc.gov/vaccines/covid-19/downloads/pre-vaccination-screening-form.pdf>

COVID-19 Vaccine for Children | AAP:

<https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/covid-19-vaccine-for-children/>

Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>

Preparing for Potential Management of Anaphylaxis | CDC:

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html>

COVID-19 Clinical Consultation | CDC:

<https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html>

Ask The Experts | Immunization Action Coalition:

[https://www.immunize.org/askexperts/experts\\_cov.asp](https://www.immunize.org/askexperts/experts_cov.asp)

## External Resources

Provider Relief Fund | HRSA:

<https://www.hrsa.gov/coviduninsuredclaim>

V-safe Print Resources | CDC:

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe/printresources.html>

VAERS Video Instructions | YouTube:

<https://youtu.be/sbCWhcQADFE>

COVID-19 Vaccinations | CDC:

<https://www.cdc.gov/vaccines/covid-19/>

## CDC Printable Resources

Summary Document for Interim Clinical Considerations Poster:

<https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations-poster.pdf>

COVID-19 Vaccine Administration Errors and Deviations Poster:

<https://www.cdc.gov/vaccines/covid-19/downloads/covid19-vaccine-errors-deviations-poster.pdf>

## CDC Vaccine Recipient Education

Vaccinate With Confidence:

<https://www.cdc.gov/vaccines/covid-19/vaccinate-with-confidence.html>

Talking with Patients About COVID-19 Vaccine:

<https://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.html>

Pediatric Healthcare Professionals Toolkit:

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/toolkits/pediatrician.html>

## Pfizer-BioNTech Resources

FDA Pfizer-BioNTech COVID-19 Vaccine Website - Includes Fact Sheets, FAQs, Regulatory information and translations:

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine>

Manufacturer Website:

<https://www.cvdvaccine-us.com>

CDC Website - full of vaccine specific tools and resources:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/index.html>

- Storage Summary:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-summary.pdf>

- Preparation Summary:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/prep-and-admin-summary.pdf>

- Standing Orders:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/standing-orders.pdf>

- Preparation Info Graphic:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/storage-summary.pdf>

## Moderna Resources

FDA Moderna COVID-19 Vaccine Website - Includes Fact Sheets, FAQs, Regulatory information and translations:

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine>

Manufacturer Website:

<https://www.modernatx.com/covid19vaccine-eua/providers>

CDC Website - full of vaccine specific tools and resources:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>

Storage Summary:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf>

Preparation Summary:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/prep-and-admin-summary.pdf>

Standing Orders:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/standing-orders.pdf>

## Janssen Resources

FDA Janssen COVID-19 Vaccine Website - Includes Fact Sheets, FAQs, Regulatory information and translations:

<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine>

Manufacturer Website:

<https://www.janssencovid19vaccine.com>

CDC Website - full of vaccine specific tools and resources:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html>

Storage Summary:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/janssen-storage-handling-summary.pdf>

Preparation Summary:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/Janssen-Prep-and-Admin-Summary.pdf>

Standing Orders:

<https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/downloads/Janssen-Standing-Orders.pdf>